January 2021 - PsychedelicNewsWire (PNW)

FridayJan 29, 2021 1:15 pm

You Don’t Have to Take Psychedelics to Benefit from Them — Here’s How

Psychedelics have been in the spotlight for quite a while now and may be here to stay, given the immense therapeutic potential various psychedelic substances have demonstrated. For instance, psilocybin mushrooms have been used in therapeutic settings to help deal with various psychiatric disorders such as anxiety or addiction; the state of Oregon as gone so far as to legalize its medicinal use. In addition to this, MDMA phase 3 trials are currently being conducted, with many predicting that there could be an FDA-approved MDMA prescription treatment by the year 2023. Researchers are studying MDMA and its efficacy in the…

ThursdayJan 28, 2021 2:30 pm

First Psychedelics ETF in the World to Be Launched This Week

Horizon ETFs will be launching the first psychedelics exchange-traded fund in the world this week. This comes after the company announced that it had filed its final prospectus to introduce PSYK, its psychedelic stock index ETF. NEO Exchange has conditionally approved units of this stock for listing, with plans to start trading on Jan. 27, 2021. The stocks will be traded under the ticker PSYK. This will give investors a chance to buy stocks in a company that is focused on developing therapeutic solutions through the use of psychedelics. Extensive clinical research has shown that various psychedelic compounds have the…

ThursdayJan 28, 2021 11:45 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Increases Private Placement, Begins Trading on OTC Market

Pure Extracts upsizes private placement to total 16,900,000 special warrants at price of $0.505. PULL also received approval from OTC Markets, is trading on OTC Market under ticker symbol PRXTF. Trading under new OTC ticker is “major step forward,” says Company CEO. Pure Extracts Technologies (CSE PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company, has increased its non-brokered private placement offering of special warrants; the original offering was announced on Dec. 16, 2020. The company also received approval from OTC Markets and is now trading on the OTC Market under the ticker symbol PRXTF. The Company observed that the…

WednesdayJan 27, 2021 3:00 pm

Advocates Worried by Insufficiency of Information on Psychedelic Treatments in Nova Scotia

Justin Andrews, co-founder of Halifax Psychedelic Society, a not-for-profit organization providing a safe space to connect and talk about psychedelics, is concerned that information on harm minimization strategies with regard to psychedelics is not being treated as a priority in Nova Scotia. Andrews assisted in the establishment of the organization in 2018. The objective of the organization was to offer harm-reduction information and a support system to individuals who would be interested in using psychedelic substances such as LSD and psilocybin as a therapeutic treatment. In this respect, harm-minimization strategies would comprise information about how to consume the psychedelic substances…

TuesdayJan 26, 2021 3:00 pm

Mount Sinai Opens Psychedelics Research Center

A new facility for psychedelics research, the Center for Psychedelic Psychotherapy and Trauma Research, was recently opened in New York City. The center follows a multifaceted research and clinical approach to finding new and more effective treatments for anxiety, depression, PTSD and other conditions linked to stress in both the civilian and veteran populations. The facility’s research will center on the study of psilocybin, MDMA and other psychedelic substances. MDMA, which is commonly known as ecstasy, is a psychoactive drug that may be used as a PTSD therapy treatment. Earlier in 2017, the U.S. FDA granted Breakthrough Therapy Designation status…

MondayJan 25, 2021 12:00 pm

Could Psychedelic Medicines Soon Be Widely Available in the UK?

Before psychedelic drugs returned to mainstream media, heralded and backed by all this new research that shows the therapeutic benefits and potential they may possess, many had known these substances to be drugs used by hippies and party-goers. As the public perception of these substances changes, many ask, what is the possibility of the use of psychedelic medical treatment in the United Kingdom? Last year, the MHRA (Medicines and Healthcare products Regulatory Agency) authorized a clinical trial that would look into the potential of DMT as a treatment for various mental health conditions, such as depression. In addition to this,…

FridayJan 22, 2021 11:45 am

Combat Sports Turn to Psychedelics as a Potential Treatment for Brain Injuries

If you watch a lot of combat sports, you probably know that fighters take a risk every time they step into the ring. This is because fighters know, whether they’re in the UFC Octagon or a typical boxing ring, they’re going to get hit in the head. It doesn’t matter what causes the hit —an elbow, knee, foot or fist — the brain still suffers trauma. Despite strides that have been made in research to understand why and how trauma is caused, as well as the long-term impact of said trauma, much about brain injuries remains unknown. Currently, new research…

ThursdayJan 21, 2021 3:15 pm

Local Legislators in Massachusetts Unanimously Vote to Decriminalize Psychedelics

Last week, local legislators in Massachusetts unanimously confirmed their support for a resolution that would decriminalize various psychedelics. The Somerville City Council heard the testimony of two individuals who had benefitted personally from the use of psychedelics therapeutically before approving the measure in a 9-0 vote. This measure was also backed by the mayor. In addition to this, some council members debated the possible medical value of psychedelic substances, especially in mental health issues, as well as the failures of the drug war. In a written statement to legislators, the Heroic Hearts Project, Bay Staters for Natural Medicines and Decriminalize…

WednesdayJan 20, 2021 2:15 pm

Cybin Inc. (NEO: CYBN) Announces Partnership with Neurotech Pioneer to Leverage Innovative Technology for Psychedelic Therapeutics

CYBN partners with pioneer company focused on exploring, quantifying the human mind Innovative Flow technology adds exciting dimension to Cybin’s commitment to develop breakthrough treatments for mental health disorders Innovative technology opens new frontier in psychedelic therapeutics Cybin (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is partnering with neurotech pioneer HI, LLC dba Kernel to quantify brain activity in real time during psychedelic experiences (https://ibn.fm/3AG5G). CYBN plans to do this by leveraging Kernel Flow, Kernel’s breakthrough technology, for its upcoming clinical work. “Access to Kernel’s innovative Flow technology adds another exciting dimension to…

WednesdayJan 20, 2021 2:00 pm

Researchers to Test Virtual Psychedelics on AI to Help Understand Effects on Human Brains

While psychedelics gain popularity across the media through various clinical trials and research studies, it is important to remember that there is still a lot about them that we don’t know, including how they cause strange hallucinations and how they affect the brain. Because psychedelics cannot be easily tested on humans, researchers from the University of Geneva and Imperial College London are working on testing virtual psychedelics on artificial intelligence (“AI”) algorithms. This will help researchers learn more about psychedelic substances while also exploring how artificial intelligence responds to a substance that is known to influence the brain of humans.…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

Month: January 2021